Literature DB >> 30205911

Management of osteoradionecrosis of the jaws with pentoxifylline-tocopherol: a systematic review of the literature and meta-analysis.

A Kolokythas1, J T Rasmussen2, J Reardon2, C Feng3.   

Abstract

Osteoradionecrosis (ORN) of the jaws remains among the most commonly encountered and challenging complications of radiotherapy to the head and neck. The purpose of this study was to provide a review of the medical management for ORN and evaluate the reported outcomes with the use of pentoxifylline and tocopherol (PENTO), by means of a systematic review and meta-analysis. The predictor variable was the use of PENTO in the treatment of ORN. The outcome variable was the proportion of full recovery or significant improvement not requiring further intervention. The likelihood function was used to combine the studies and estimate the proportion and standard deviation of each outcome by the maximum likelihood estimation. Seven studies met the inclusion criteria. A total 211 patients were treated. One hundred twenty-six patients recovered fully or improved significantly not requiring further intervention. Sixty patients remained the same, 10 were lost to follow-up, and the disease progressed in 15. The current literature supports the use of PENTO in the treatment of ORN of the jaws. Additional well-designed prospective studies are needed in order to further validate the regimen that can then be employed in the treatment of ORN.
Copyright © 2018 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ORN; PENTO; medical management; meta-analysis; systematic review

Mesh:

Substances:

Year:  2018        PMID: 30205911     DOI: 10.1016/j.ijom.2018.08.007

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  8 in total

1.  Aggressive Treatment Including Endonasal Surgical Sequestrectomy with Vascularized Nasoseptal Flap Can Improve Outcomes of Skull Base Osteoradionecrosis.

Authors:  Sung-Woo Cho; Sang Y Han; Yoonjae Song; Jeong-Whun Kim; Hyun J Kim; Dong-Young Kim; Chae-Seo Rhee; Yun J Bae; Ji-Hoon Kim; Hong-Gyun Wu; Jae S Bang; Tae-Bin Won
Journal:  J Neurol Surg B Skull Base       Date:  2021-01-14

Review 2.  CD73, Tumor Plasticity and Immune Evasion in Solid Cancers.

Authors:  Haitang Yang; Feng Yao; Paul F Davis; Swee T Tan; Sean R R Hall
Journal:  Cancers (Basel)       Date:  2021-01-07       Impact factor: 6.639

3.  Refining the mandibular osteoradionecrosis rat model by in vivo longitudinal µCT analysis.

Authors:  Morgane Dos Santos; Christelle Demarquay; Louis Ermeneux; Fazia Aberkane; Pauline Bléry; Pierre Weiss; Fabien Milliat; Noëlle Mathieu
Journal:  Sci Rep       Date:  2021-11-15       Impact factor: 4.379

Review 4.  A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19.

Authors:  Gomaa Mostafa-Hedeab; Hayder M Al-Kuraishy; Ali I Al-Gareeb; Philippe Jeandet; Hebatallah M Saad; Gaber El-Saber Batiha
Journal:  Inflammopharmacology       Date:  2022-04-29       Impact factor: 5.093

Review 5.  Dental Evaluation Prior to Cancer Therapy.

Authors:  Chee Weng Yong; Andrew Robinson; Catherine Hong
Journal:  Front Oral Health       Date:  2022-04-18

Review 6.  Osteoradionecrosis of the jaw: A mini review.

Authors:  Annu Singh; Joseph M Huryn; Kenneth L Kronstadt; SaeHee K Yom; Joseph R Randazzo; Cherry L Estilo
Journal:  Front Oral Health       Date:  2022-07-28

7.  Three-dimensional (3D) anatomic location, extension, and timing of severe osteoradionecrosis of the mandible.

Authors:  Lucas G Sapienza; Justin J Thomas; Weiyuan Mai; Alexander N Hanania; Sandeep Hunjan; Vlad C Sandulache; Albert C Chen
Journal:  Rep Pract Oncol Radiother       Date:  2022-07-29

8.  Temporal Bone Osteoradionecrosis: An 18-year, Single-Institution Experience.

Authors:  Benjamin D Lovin; Mike Hernandez; Hunter Elms; Jonathan S Choi; Nathan R Lindquist; Amy C Moreno; Marc-Elie Nader; Paul W Gidley
Journal:  Laryngoscope       Date:  2021-07-20       Impact factor: 2.970

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.